Chromosomal translocations of transcription factors generating fusion proteins with aberrant transcriptional activity are common in acute leukemia. In acute promyelocytic leukemia (APL), the promyelocytic leukemia-retinoic-acid receptor alpha (PML-RARA) fusion protein, which emerges as a consequence of the t(15;17) translocation, acts as a transcriptional repressor that blocks neutrophil differentiation at the promyelocyte (PM) stage. In this study, we used publicly available microarray data sets and identified signatures of genes dysregulated in APL by comparison of gene expression profiles of APL cells and normal PMs representing the same stage of differentiation. We next subjected our identified APL signatures of dysregulated genes to a series of computational analyses leading to (i) the finding that APL cells show stem cell properties with respect to gene expression and transcriptional regulation, and (ii) the identification of candidate drugs and drug targets for therapeutic interventions. Significantly, our study provides a conceptual framework that can be applied to any subtype of AML and cancer in general to uncover novel information from published microarray data sets at low cost. In a broader perspective, our study provides strong evidence that genomic strategies might be used in a clinical setting to prospectively identify candidate drugs that subsequently are validated in vitro to define the most effective drug combination for individual cancer patients on a rational basis.
Introduction
Acute myeloid leukemia (AML) encompasses a variety of clonal disorders, whose malignant populations comprise hematopoietic stem/progenitor cells (HSC/HPCs, 'blasts') that do not respond normally to regulatory cues and have lost the ability to differentiate into fully mature blood cells. Comprehensive microarray studies in AML have provided AML expression profiles, which correlate well with the cytogenetic and molecular genetic aberrations that in concert with morphological characteristics form the basis for today's WHO (World Health Organization) classification of AML subtypes. [1] [2] [3] In other words, these studies have shown that AML expression profiles represent distinct biological states or phenotypes that, at least in part, emerge as a consequence of specific genetic aberrations. Hence, comparison of expression profiles of leukemic and normal hematopoietic cells representing the same stage of differentiation might help to uncover genes dysregulated in leukemic cells that potentially contribute to malignant transformation.
Acute promyelocytic leukemia (APL) comprises 5-10% of all AMLs and is characterized by a block in terminal neutrophil differentiation and the accumulation of 'leukemic' promyelocytes (PMs) (APL cells) in the bone marrow (BM) and blood. Over 98% of APLs harbor a t(15;17) translocation, which juxtaposes the promyelocytic leukemia gene (PML) and the retinoic-acid receptor alpha gene (RARA) resulting in the expression of the PML-RARA fusion protein. 1, 4, 5 In normal cells, RARA forms heterodimers with the retinoid X receptor, which binds the retinoic acid (RA) responsive elements of their target gene promoters. In the absence of RA, RARA interacts with histone deacetylase (HDAC)-containing co-repressor complexes and represses transcription, whereas binding of RA triggers a conformational switch resulting in release of corepressor complexes and recruitment of co-activator complexes (containing histone acetyl transferases), and subsequently, activation of transcription. 4, 6 In APL cells, PML-RARA forms homodimers, multimeric complexes and heterodimers with retinoid X receptor that all bind to retinoic acid responsive element and repress transcription at physiological levels of RA through recruitment of co-repressor complexes containing HDACs, DNA methyltransferases and polycomb histone methyltransferases. 4, [7] [8] [9] [10] At pharmacological levels, however, RA reverses PML-RARA mediated repression of RARA target genes resulting in terminal neutrophil differentiation of APL cells. 4, 5 Although these findings highlight the progress in our understanding of how PML-RARA represses transcription at the molecular level, little is currently known regarding the gene-expression signature that emerges as a consequence of PML-RARA and secondary genetic aberrations in human APL.
In this study, we used publicly available microarray data sets from APL cells and human BM sub-populations and applied a set of computational analyses to define APL signatures of dysregulated genes that might contribute to malignant transformation. This leads to the discovery that dysregulated genes in APL cells share regulatory features associated with stemness. In agreement with this finding, APL cells were found to differ form their normal counterparts (that is, PMs) by partial expression of a stemness signature. Finally, correlation of APL signatures with expression signatures from drug treatments identified candidate drugs that might be used as supplements in current APL treatment protocols.
Materials and methods
An outline of our analysis strategy including all databases and computational tools described in detail below are depicted in Figure 1 .
Microarray analysis
Microarray data sets were selected from published studies using Hu133A GeneChips (Affymetrix, Santa Clara, CA, USA) for expression profiling (Supplementary Table 1) . 2, 3, [11] [12] [13] [14] Data sets were imported from the GEO database (www.ncbi.nlm. nih.gov/geo) and normalized using the statistical software R/BioConductor and the gcRMA algorithm. 15, 16 This study contained microarray data sets from patients with hypergranular APL (that is, AML FAB M3) including APL patients with FLT3-ITD mutations (n ¼ 5), FLT3-TKD mutations (n ¼ 5) and neither of the two mutations (n ¼ 16). Microarray data sets of the hypogranular APL variant (that is, AML FAB M3v) were excluded from the study. Microarray data sets from normal human BM sub-populations included
(n ¼ 3), myelocytes/metamyelocytes (Mys, n ¼ 3), BM and peripheral blood neutrophils (bm-/pb-PMNs, n ¼ 3), CD14 þ monocytes (MO, n ¼ 3) and whole normal BM cells (n ¼ 3).
Correlation analysis
To assess the similarity between our different populations, we compared the global expression profiles by calculating a Pearson rank correlation between all samples, and used these values as input for hierarchical clustering. The resulting clusters are used to select the best possible correlate for our stemnessand APL-expression signatures discussed below.
Gene-expression signatures and gene set enrichment analysis (GSEA)
Gene-expression signatures were defined as ranked lists of differentially expressed genes between two populations, for example, APL versus PM. For all expression signatures, genes were ranked according to their signal-noise ratio, which was defined as the difference in mean expression between two populations over the sum of the s.d. of the two populations. Gene ranks in a given expression signature and the corresponding real value acted as input variables to the GSEA described below.
GSEA assesses whether an a priori defined set of genes is randomly distributed in a ranked list of expression values between two distinct cell populations, or primarily associated with either of the two. 17 An enrichment score is calculated for the given gene set and based on a permutation strategy a null distribution is derived. The empirical nominal P-value is calculated relative to this null distribution. Figure 1 Conceptual framework for the identification of candidate drugs and drug targets: the figure shows a flow chart of our analysis strategy including all databases and computational tools described in detail in the text. Briefly, GEO microarray gene expression profiles of acute promyeloyte leukemia cells (APL), normal promyelocytes (PM), hematopoietic stem cells (HSC), early hematopoietic progenitor cells (HPC) and APL cells differentiated by 5 days treatment of all-trans retinoic acid (APL-RA) were used to generate APL-, stemness-and APL-RA signatures. The identified signatures were subjected to a series of computational analyses using various bioinformatics tools (gene set enrichment analysis (GSEA), promoter analysis and randomForest analysis) and public available databases providing (i) position weight matrixes for TF binding sites (JASPAR and TRANSFAC) and (ii) drug signatures (connectivity MAP (CMAP)). The identified drug candidates were validated in vitro using the human APL cell line (NB4).
To test for an association between our stemness and APL gene-expression signatures we used GSEA. 17 Briefly, a stemness signature was defined as the 100 top-ranked probe sets in HSCs versus early HPCs ranked by signal-noise ratio (Supplementary Table 2 ). The APL signatures included all expressed genes in APL cells ranked by signal-noise ratio versus PMs. Supplementary Table 2 provides a selected list of the 100 top-ranked genes for all APL signatures. P-values were calculated by permuting the stemness and APL signatures according to the GSEA guidelines for low numbers of samples (www.broad.mit.edu/ gsea). 17 
Promoter analysis
Promoter analyses were conducted using the ASAP-framework and position weight matrices (that is, transcription factor (TF) binding site matrices) from the JASPAR database. 18, 19 Additional relevant position weight matrices, namely the RARA-half site, DR1, T3R, XBP1 and EGR1 were downloaded from the TRANSFAC database version 10.4. 20 To dissect the transcriptional regimes in APL cells versus PMs and HSCs versus early HPCs, we identified the promoter regions for genes up-or downregulated in APL cells versus PMs and for genes upregulated in HSCs versus early HPC (signal-noise ratio 41). Using these promoter regions, the number of the computationally predicted binding sites for any given TF within each sample was recorded. The relative differences in TF binding site occurrences between samples were defined by a Z-score. Assuming independence between TF binding site and sample the number of occurrences of a TF binding site only depends on the number of promoter regions in the given sample. Thus, given the total number of TF binding sites detected for a given TF, we defined the expected number of occurrences based on the individual sample sizes, and calculated a Z-score based on the observed number of occurrences. The sign and magnitude describes the relative over-or under-representation of a given TF binding site within the promoters of the differentially expressed genes in APL cells versus PM and HSCs versus early HPCs. Promoter regions were defined as À1000 to þ 200 bp relative to the annotated initiation site and included both DNA strands.
Connectivity MAP (CMAP) analysis
To identify drug candidates for APL treatment, we queried the connectivity MAP (CMAP; http://www.broadinstitute.org/ cmap/) database using three different GSEA generated gene sets representing signatures of stemness (HSC versus early HPC), APL (APL versus PM) and APL-RA (APL treated by all-trans RA (ATRA) for 5 days versus APL untreated). 12, 21, 22 The stemness signature contained the top 100 ranked probe sets in HSCs versus early HPCs (Supplementary Table 2 ). The APL and the APL-RA signatures contained the 499 top-ranked and the 499 bottom-ranked probe sets (CMAPs maximum input size) (Supplementary Table 2 provides a list of the 100 top-ranked genes). All three signatures were queried using drug signatures of the HL-60 leukemia cell line (HL-60 treated with drug versus untreated HL-60 cells), which like APL cells differentiate in response to ATRA. Drug candidates were defined by their capacity to repress genes in HL-60 cells that are upregulated in the stemness and APL signatures, and to upregulate genes in HL-60 cells that are upregulated in APL cells after treatment with ATRA (APL-RA signature). Drug signatures with a positive correlation above or equal to 0.6 in our APL-RA query and negative correlations below or equal to -0.6 in our stemness and APL queries were defined as relevant.
Surface antigens
The absolute expression values for 182 leukocyte surfacemolecules that have been assigned a cluster of differentiation (CD) number (http://www.expasy.org/cgi-bin/lists?cdlist.txt) were extracted from our expression database, and divided into two groups containing either all APL-samples or samples of all normal BM sub-populations representing successive stages of differentiation. 23 Next, randomForest and varSelRF algorithms in R were used to identify CD molecules that allow to classify the two groups of samples. 24 
Drug tests
The human APL cell line NB4 was maintained in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum and 1% penicillin-streptomycin (Invitrogen). For drug testing 1 Â 10 5 NB4 cells/ml (1 ml per well) were seeded in 24-well plates and incubated with candidate drugs at indicated concentrations in triplicate ( Figure 6 ). Controls were incubated with medium alone or medium supplemented with 1 mM ATRA (control for standard differentiation therapy), or 1 mM dimethyl sulfoxide (control for drugs stored in dimethyl sulfoxide). All candidate drugs, ATRA and dimethyl sulfoxide were provided by Sigma (Sigma-Aldrich, St Louis, MO, USA). The effect of drugs on cell proliferation was assessed by cell enumeration using an automated cell counter (Innovatis, Casy Systems, Reutlingen, Germany). Cell viability was assessed by propidium iodide staining (Invitrogen) and subsequent flow cytometry analysis using a FACS Calibur flow cytometer (Becton Dickinson, BD Biosciences, Franklin Lakes, NJ, USA). Data were analyzed using the FlowJo software package (TreeStar, Ashland, OR, USA).
Results

Identification of dysregulated genes in APL cells
In an attempt to delineate genes associated with malignant transformation in human hypergranular APL (that is, AML FAB M3), we compared gene expression profiles of APL cells and their normal counterparts (that is, PMs), and other normal human BM sub-populations including HSCs (CD34 þ CD38À CD33ÀCD117 þ Rhodamine low), early HPCs (CD34 þ CD38À CD33ÀRhodamine high), CD34 þ cells, myelocytes/metamyelocytes (MYs), BM and peripheral blood neutrophils (bm-/pbPMNs), CD14 þ monocytes (MO) and whole normal BM cells.
To define a quantitative measure reflecting the developmental distance between APL cells and BM sub-populations, we assessed the Pearson correlation coefficients (g) between all populations by pairwise correlation of their gene expression profiles, and used those values as input for hierarchical clustering ( Figure 2 ). This analysis showed the strongest correlation between APL cells and PMs, implicating that PMs represent a developmental stage most similar to that of APL cells not only by morphology but also at the gene expression level. We therefore reasoned that genes differentially regulated in APL cells compared with PMs would constitute the best possible correlation of an APL signature of dysregulated genes promoting malignant transformation. Using microarray data sets from two APL studies, we defined five signatures of APLs with or without ITD and TKD mutations of the FLT3 receptor (referred to as APL1, APL1-ITD/TKD, and APL2, APL2-ITD, APL2-TKD) that were used for subsequent analysis.
3,11
Transcriptional regime of genes dysregulated in APL
To analyze the regulatory features associated with malignant transformation in APL, we performed a comprehensive promoter analysis of genes differentially regulated in APL cells versus PMs (Figure 3 ). For this, we applied all TF binding site models in the JASPAR database, and supplementary models from the TRANS-FAC database (that is, RARA-half site, DR1, T3R, XBP1 and EGR1). We next calculated the relative abundance of TF binding sites in the promoter regions of genes that were significantly upor downregulated in APL cells versus PMs, and clustered these binding sites according to their regulatory potential ( Figure 3) . It is important to point out that the reported transcriptional regimes were defined using a discriminatory approach. That is, by direct comparison of the promoter sequences in PMs and APL cells our analysis defines to what extend the sequence landscapes are identical, and what regulatory features are shared between the different samples.
Interestingly, our analysis revealed that binding sites for CCAAT/enhancer-binding protein alpha (CEBPA), which is a key-regulator of neutrophil differentiation, were overrepresented among genes downregulated in APL cells versus PMs. 25, 26 In contrast, genes upregulated in APL cells versus PMs contained a significant enrichment of binding sites for TFs that are instrumental for malignant transformation in cell lines and AML (MZF1, ARNT), and most strikingly for proliferation, mobilization and self-renewal of HSCs and/or leukemic stem cells (LSCs) (ERG1, NFKB, NFKB1). [27] [28] [29] [30] [31] [32] APL cells show a partial stemness signature Our promoter analysis revealed that genes upregulated in APL cells versus PMs were significantly enriched in binding sites for TFs that conduct HSC maintenance/self-renewal. This led us to the hypothesis that APL cells might differ form PMs by expression of genes associated with HSC maintenance/selfrenewal. To test this, we first constructed a 'stemness-'expression signatureFthat is, a list of the top 100 ranked genes expressed in HSCs compared with early HPCs. We then applied the GSEA framework to test the similarity of our APL signatures . Microarray data sets of the hypogranular APL variant (that is, AML FAB M3v) were excluded from the study. Microarray data sets from normal human BM sub-populations included hematopoietic stem cells (BM-HSC,CD34 þ CD38ÀCD33ÀCD117 þ Rhodamine low, n ¼ 4), early hematopoietic progenitors (BM-HPC, CD34 þ CD38ÀCD33ÀRhodamine high, n ¼ 4), promyelocytes (PMs, n ¼ 3) myelocytes/metamyelocytes (MYs, n ¼ 3), BM and peripheral blood neutrophils (bm-/pb-PMNs, n ¼ 3), CD14 þ monocytes (MOs, n ¼ 3). and the stemness signature. It is noteworthy that this analysis revealed a significant association across all five APL signatures with the stemness signature (P-value o0.05) (Figure 4) . Consistent with this finding, inclusion of the stemness signature genes in the promoter analysis described in the previous section revealed that genes upregulated in HSCs versus early HPCs and genes upregulated in APL cells versus PMs were significantly enriched for the same TF binding sites. In other words APL and stemness signature genes are similar in terms of promoter features (Figure 3) .
These findings show that APL cells differ from PMs by partial expression of a stemness signature in spite of both cell types otherwise show a highly similar expression profile.
Identification of candidate drugs for the treatment of APL
The current standard regimes for APL therapy all include combinations of ATRA 33 and anthracycline-based chemotherapy. 5 Despite this, these regimens have markedly increased the rate of complete remission and the long-term outcome of APL patients, approximately 10-30% of patients will suffer from recurrent disease within a period of 5 years. 5, 34, 35 This clinical outcome implicates that ATRA/anthracycline therapy will not target dysregulated genes and pathways sufficiently in all APL patients.
We reasoned that our APL and stemness signatures could be used to screen for candidate drugs targeting dysregulated genes in APL cells. However, such predicted candidate drugs would not necessarily mimic the effect of ATRA treatment and induce differentiation of APL cells. We therefore generated an expression signature for ATRA-treated APL cells (APL-RA signature, see Materials and methods section on CMAP), as the ideal drug response should both target the APL/stemness signatures while at the same time induce a differentiation signature similar to that observed with ATRA treatment.
We next applied the GSEA framework to correlate our APL, stemness and APL-RA signatures, with a collection of expression signatures for 41300 bioactive compounds provided by the CMAP database (www.broad.mit.edu/cmap). To identify relevant drug candidates for the treatment of APL, we searched for compounds, which induce gene-expression signatures in the HL-60 leukemia cell line that are inversely correlated with our APL signatures. 21, 22 As discussed above, the rationale for this approach is that a compound, which can reverse expression of dysregulated genes in APL, represents a drug candidate for the treatment of APL. We further screened the CMAP database for HL-60 drug signatures correlating inversely with the stemness Figure 3 Heat map of TF binding sites: to define the transcriptional machinery contributing specifically to the APL and stemness signatures we performed a promoter analysis to identify TFs whose binding sites were significantly overrepresented among genes up-or downregulated in acute promyelocytic leukemia cells (APL cells) versus normal promyelocytes (PMs) and hematopoietic stem cells (HSCs) versus early hematopoietic progeniors (HPCs). The promoter analysis included promoter regions of differentially expressed genes with a signal-noise ratio above 1. Promoter regions were defined as À1000 to þ 200 bp relative to the annotated initiation site including both DNA strands. TF binding sites were identified using the ASAP framework and a combination of position weight matrices from the JASPAR and TRANSFAC databases. The heat map shows the densities of predicted TF binding sites among genes upregulated in APL cells versus PMs (columns of five APL groups), genes downregulated in APL cells versus PM (columns of five PM-APL groups) and genes upregulated in HSCs versus early HPCs (column of stemness group). Rows represent densities of predicted TF binding sites and are depicted as Z-scores, ranging from À30 (strong under-representation corresponding to blue color) up to þ 30 (strong over-representation corresponding to red color). The names of the TFs predicted to associate with the identified binding sites are indicated to the left. Columns and rows are clustered according to similarity. signature and positively with a signature of APL cells treated with ATRA (APL-RA signature) to identify compounds that can reverse expression of stemness genes as well as induce expression of genes associated with differentiation, respectively. Overall, our drug screening strategy identified three compounds that induced downregulation of APL and stemness genes concomitant with upregulation of differentiation associated genes in the HL-60 leukemia cell line (Supplementary Figure 1) . The identified compounds included a HDAC inhibitor (Trichostatin A), an inhibitor of phosphoinositide 3-kinase (PI3K) (LY294002) and an inhibitor of phospholipase A2 (PLA2) (Quinacrine), which all have been shown to inhibit proliferation and/or induce apoptosis in various types of cancers including AML. Significantly, the ATRA drug signature of HL-60 cells correlated both with the APL-RA signature (positively) and the APL signature (inversely) but not with the stemness signature. The latter implicates that the three identified compounds at least in part might affect APL cells by mechanisms complementary to the differentiation effect of ATRA.
Validation of candidate drugs
To validate the identified candidate drugs in our in silico screen, we used the NB4 cell line, which originates from a patient with APL (FAB M3) and resembles APL cells in many ways. First, it has a PM morphology, second, it harbors a t(15;17) translocation and expresses the PML-RARA fusion protein and finally, it retains a gene expression profile similar to that of primary APL cells and differentiates in response to ATRA treatment. 36, 37 Incubation of NB4 cells with Trichostatin A, LY294002 and Quinacrine for 48 h resulted in a marked inhibition of proliferation and induction of apoptosis at micromolar concentrations ( Figure 5 ). These findings implicate that the applied in silico screening strategy provides a powerful tool for the identification of candidate drugs targeting APL cells.
We next extended our search for candidate drugs using an alternative strategy. With this strategy, we hypothesize that inhibitors of TFs, which control expression of dysregulated genes in APL, might indeed represent potential candidate drugs. To test this strategy, we focused our efforts on the TF nuclear factor (NF)-kB, in part, because our promoter analysis revealed a significant enrichment of binding sites for NF-kB among genes dysregulated in APL, and in part, because NF-kB can be inhibited effectively by terpenoids such as Parthenolide. 32, 38 Significantly, incubation of NB4 cells for 48 h with micromolar concentrations of Parthenolide resulted in a substantial inhibition of proliferation and induction of apoptosis ( Figure 5 ). The latter suggests that comprehensive promoter analysis of dysregulated genes in APL can identify TFs, which at least to some extent, might represent potential targets for therapeutic interventions.
Identification of APL-specific surface antigens
In addition to the identification of drug candidates, we aimed to identify surface antigens that are highly expressed by APL cells but not by normal BM populations, and thus might represent target antigens for immunotherapy. For this, we generated a list including expression profiles for 182 leukocyte surface antigens that have been assigned a CD number, and subsequently applied the randomForest algorithm to identify those CD molecules that would discriminate APL cells from normal BM populations. Although the primary task of this algorithm is to define a combination of CD molecules that can discriminate APL cells from normal BM populationsFit will at best identify CD molecules, whose transcripts are exclusively expressed in APL cells but not in any of the normal BM populations. Among the discriminative CD molecules (CD33, CD62L, CD96, CD99, CD123, CD133) identified in our analysis, the CD96 molecule was the only one whose transcripts were highly expressed in almost all APL samples (23 out of 26) but not in any of the normal BM populations ( Figure 6 ). Hence, our findings suggest that the CD96 surface molecule represents a promising target antigen for future immunotherapy of APL patients. However, future flow cytometry studies are required to validate whether CD96 is expressed at the protein level in primary APL cells.
Discussion
Recent studies in mice have shown that genes critical for maintenance/self-renewal of AML can be identified among those genes that are differentially regulated in AML progenitors and wild-type HPCs representing the same stage of differentiation. 39, 40 In alignment with this conceptual proof of principle, this study identified signatures of genes dysregulated in a human leukemia subtype, namely APL, by comparison of gene expression profiles of APL cells and normal PMs representing the same stage of differentiation. The APL signatures of dysregulated genes were subsequently subjected to a series of computational analyses resulting in (i) the finding that APL cells show stemness properties in terms of gene expression and transcriptional regulation, and (ii) the identification of candidate drugs and drug targets. Together, the strategy applied in our study strongly suggests that much can be learned from mining publicly available data in a biological relevant context. Moreover, our study showed the feasibility of integrating micorarray data from different studies, which is in agreement with the recent MicroArray Quality Control project reporting a high intraplatform consistency among various laboratories. 41 Hence, integrating publicly available data with data from new studies represent an useful strategy to increase the power of statistical tests as well as significantly reduce the time and cost of performing additional experiments.
The microarray data sets used in this study included expression profiles from APL cells before and after ATRAinduced differentiation, as well as profiles from highly enriched human BM populations representing distinct stages of differentiation. It is important to point out that the APL microarray data sets were generated from BM aspirates containing X80% Figure 5 Validation of candidate drugs: for drug testing the APL cell line, NB4, was incubated with candidate drugs in triplicate (n ¼ 3) at indicated concentrations. Controls were incubated with medium alone. In addition, NB4 cells were incubated in medium supplemented with either 1 mM all-trans retinoic acid (ATRA; control for standard differentiation therapy), or 1 mM dimethyl sulfoxide (DMSO; control for drugs stored in DMSO). The effect of drugs on cell proliferation was assessed by cell enumeration, and cell viability was assessed by propidium iodide staining and subsequent flow cytometry analysis. The cell numbers and percentage of dead cells are given as the fold-change relative to NB4 cells incubated with medium alone (n ¼ 3; mean ± s.d.). Abbreviations: Trichostatin A (TSA), Quinacrine (Q), L294002 (LY), Parthenolide (P).
APL blasts and therefore might contain a minor fraction non-myeloid cells that might affect the obtained gene expression profiles. However, markers highly expressed in T-, B-, NK-, megakaryocytic and erythroid cells were either not detected or expressed at low levels in APL cells compared with whole BM cells from healthy individuals (data not shown). The latter suggests that non-myeloid cells do not contribute essentially to the obtained APL expression profiles in this study.
To delineate the transcriptional regime that emerges in APL cells as a consequence of PML-RARA and secondary genetic aberrations, we performed a comprehensive promoter analysis of genes differentially regulated in APL cells versus PMs. This analysis revealed that binding sites for CEPBA-were significantly enriched among genes upregulated in PMs but not among genes upregulated in APL cells. In as much CEPBA represents a key-regulator of neutrophil differentiation these findings suggest that the transcriptional regime in APL cells at least in part blocks neutrophil differentiation by repression of CEPBA target gene transcription. 25, 26 Indeed this notion is supported by a recent study showing that PML-RARA conduct partial silencing of CEPBA target genes through DNA methylation of its promoter regions. 42 The promoter analysis also showed that genes upregulated in APL cells versus PMs contained a significant enrichment of binding sites for TFs that propagate proliferation, mobilization and self-renewal of HSCs/LSCs. Among these we identified binding sites for NF-kB suggesting that enhanced activation of NF-kB target genes (Supplementary Table 3 ) might contribute to malignant transformation in APL. Significantly, this was supported by in vitro studies showing that NF-kB inhibitors reduced proliferation and induced apoptosis in an APL cell line.
Overall, these findings indicate that APL cells are governed by a transcriptional regime that can promote stemness properties while lacking the ability to direct differentiation. [27] [28] [29] [30] [31] [32] Moreover, these findings show the potential of comprehensive promoter analysis to identify TFs that might serve as targets for therapeutic interventions.
At present, AML is thought of as clonal disorder, which is initiated and maintained by LSCs whose progeny make up the bulk of the leukemic blast population. Hence, LSCs and normal HSCs share the capacity for infinite self-renewal and production of progeny. 43 Along with others, we showed in murine models of human AML that leukemic cells with a HPC immunophenotype expressing either a mutated CEPBA-protein or the MLL-AF9 (mixed lineage leukemia -ALL1 fused gene from chromosome 9) fusion protein can transfer AML to congenic hosts, and thus represent LSCs. Importantly, these LSCs with a HPC immunophenotype differed from their corresponding wild-type HPCs by partial expression of a stemness signature in spite of the exhibition of an identical immunophenotype. 39, 40 Collectively, these findings implicate that AML arises from LSCs that develop as a consequence of genetic aberrations in either HSCs or myeloid HPCs. In addition, these findings indicate that LSCs arising from myeloid HPCs depend on genetic aberrations, which promote self-renewal through partial expression of 'stemness' genes. Consistent with these findings, our study for the first time shows that human APL cells differ from their normal counterparts (that is, PMs) by partial expression of a stemness signature. Indeed, this observation would support a model in which human APL is maintained by myeloid HPCs expressing a partial stemness signature. This hypothesis is supported by recent studies showing that LSCs in murine APL models have a morphology and an immunophenotype similar to that of normal PMs. 42, 44 To identify drug candidates that might be used as supplements in current APL treatment protocols, we searched for compounds that generated signatures in the HL-60 leukemia cell line, which reversed our APL and stemness signatures and induced an ATRA signature in APL cells. The rationale for this strategy is to identify compounds that inhibit cellular maintenance and self-renewal by downregulation of APL and stemness genes while at the same time promoting differentiation through upregulation of ATRA-dependent genes. Significantly, our drug screening strategy identified three compounds that fulfilled all three criteria and have been shown to inhibit proliferation and/ or induce apoptosis in various types of cancers including AML by mechanisms different from those reported for ATRA and anthracyclines. Briefly, Trichostatin A, belongs to a class of drugs known as HDAC inhibitors, which antagonize HDAC activity and thereby enhance histone acetylation resulting in an open chromatin state and promotion of transcriptional activity. HDAC inhibitors have been shown to promote growth arrest, apoptosis and differentiation both in vitro and in vivo in different types of malignancies including AML and APL. 6, [45] [46] [47] [48] [49] The second compound, LY294002, inhibits the PI3K signaling enzyme, which promotes proliferation, cell survival and angiogenesis. The PI3K pathway comprises upstream tyrosine kinase receptors, PI3K itself, and the downstream effector AKT, and is frequently altered in cancers including leukemia. [50] [51] [52] The PI3K pathway is activated in chronic myeloid leukemia and acute B-cell leukemia by the BCR-ABL oncogene, a constitutively activated tyrosine kinase, and in various subtypes of AML including APL by FLT-ITD and -TKD mutations causing constitutive activation of the FLT3 tyrosine kinase receptor. 53, 54 Importantly, in vitro studies have shown that PIK3 inhibitors can induce growth arrest and apoptosis in chronic myeloid leukemia and AML by blocking downstream signaling of constitutively activated tyrosine kinases alone as well as in synergy with tyrosine kinase inhibitors (nilotinib, PKC412). 54, 55 The third compound, Quinacrine, is an inhibitor of PLA2. The PLA2s family of esterases cleaves glycerophospholipids and release fatty acids including arachidonic acid and lysophospholipids, which are essential for the generation of several active mitogenic mediators. 56, 57 In line with the mitogenic function of PLA2 pathway products, inhibitors of PLA2s have been shown to block proliferation of human breast cancer-, promonocyticand prostate cancer cell lines. 33, 58, 59 Consistent with these reports, in vitro drug tests in our study showed that all three identified compounds inhibited proliferation and induced apoptosis in an APL cell line. Significantly, these findings highlight the potential of our drug screening strategy to identify candidate drugs with antileukemic effects that might be used as supplements in current APL treatment protocols.
Monoclonal antibodies and immunoconjugates targeting surface molecules have been successfully used for the treatment of hematological malignancies including AML. [60] [61] [62] [63] In this study, we identified the CD96 molecule as the only surface molecule, whose transcripts were highly expressed in almost all APL samples (23 out of 26) but not in any of the normal BM populations ( Figure 5 ). This finding is corroborated by a recent study showing that various subtypes of AML contain a significant higher frequency of CD96 þ (CD34 þ CD38 þ ) blasts/HPCs and CD96 þ (CD34 þ CD38À) HSCs compared with their normal counterparts. 64 In this context, our findings suggest that the CD96 surface molecule represents a promising target for future immunotherapy of APL as well as other AML subtypes.
In summary, our study provides a conceptual framework (Figure 1 ) for the identification of dysregulated genes in APL as well as novel candidate drugs and targets for therapeutic interventions. Importantly, this approach can be applied to any subtype of AML to uncover novel information from published microarray data sets at low cost. In a broader perspective, a similar strategy might even be used to identify candidate drugs that subsequently are validated in vitro to define the most effective drug combination for individual AML patients on a rational basis.
